Zydus has announced that the USFDA has granted Orphan Drug Designation (ODD) to Usnoflast, a novel oral NLRP3 inhibitor, for the treatment of amyotrophic lateral sclerosis (ALS). The designation ...

The US Food and Drug Administration (FDA) has granted approval for Zydus Lifesciences to proceed with a randomised Phase IIb trial of its oral NLRP3 inflammasome inhibitor, Usnoflast, for ...

Zydus, a leading, discovery-based, global pharmaceutical company announced that the US FDA has granted Orphan Drug Designation (ODD) to Usnoflast, a novel oral NLRP3 inhibitor, for the treatment of ...

Zydus Wellness Ltd announced that its subsidiary, Zydus Wellness Products Ltd, has received a GST demand of Rs 56.33 crore with interest and penalties from the tax authority. The demand relates to ...

Zydus Lifesciences announced that it has entered into an agreement with CVS Caremark, a CVS Health (CVS) company, to add Zituvio, Zituvimet and Zituvimet XR tablets to its template formulary.

Zydus Lifesciences Limited (Formerly known as Cadila Healthcare Limited) is one of the leading innovation driven pharmaceutical companies in India with presence across the pharmaceutical value ...

Zydus Wellness Ltd share price was up by 1.60% from the previous closing price of ₹1,976.05. Who are peers of Zydus Wellness Ltd? The peers of Zydus Wellness Ltd are Hindustan Unilever Ltd ...

Zydus Wellness Limited is an India-based consumer company. The Company is focused on providing health and wellness-oriented products across two primary segments: Food & Nutrition and Personal Care ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Credit: David Herraez Calzada / Shutterstock. The US Food and Drug Administration (FDA) has granted approval for Zydus Lifesciences to proceed with a randomised Phase IIb trial of its oral NLRP3 ...